Safety and Efficacy of the Common Vaccines against COVID-19
The worldwide pandemic of coronavirus disease 2019 (COVID-19) has imposed a challenge on human health worldwide, and vaccination represents a vital strategy to control the pandemic. To date, multiple COVID-19 vaccines have been granted emergency use authorization, including inactivated vaccines, ade...
Main Authors: | Ying Liu, Qing Ye |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/4/513 |
Similar Items
-
Efficacy and Safety of COVID-19 Vaccines—An Update
by: Eshani Sharma, et al.
Published: (2022-11-01) -
Increased B Cell Selection Stringency In Germinal Centers Can Explain Improved COVID-19 Vaccine Efficacies With Low Dose Prime or Delayed Boost
by: Amar K. Garg, et al.
Published: (2021-11-01) -
The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial
by: Chunhua Zhou, et al.
Published: (2024-12-01) -
The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous schedule
by: Gretel Naidich, et al.
Published: (2023-04-01) -
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant
by: Gabiria Pastore, et al.
Published: (2024-12-01)